1. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
by Gunnar Juliusson, Petar Antunovic, Åsa Derolf, Sören Lehmann, Lars Möllgård, Dick Stockelberg, Ulf Tidefelt, Anders Wahlin, and Martin Höglund
Blood
Volume 113(18):
April 30, 2009
©2009 by American Society of Hematology

2. Incidence of AML (non-APL) in 1997 to 2005 (new cases per 100 000 inhabitants, based on the Swedish population in 2005) according to age and sex.
Incidence of AML (non-APL) in 1997 to 2005 (new cases per 100 000 inhabitants, based on the Swedish population in 2005) according to age and sex.
Gunnar Juliusson et al. Blood 2009;113:
©2009 by American Society of Hematology

3. Proportion of AML (non-APL) patients with WHO/ECOG performance status 0 to IV at diagnosis according to age.
Proportion of AML (non-APL) patients with WHO/ECOG performance status 0 to IV at diagnosis according to age. The numbers of patients are given at the bottom of the figure.
Gunnar Juliusson et al. Blood 2009;113:
©2009 by American Society of Hematology

4. Early death rates (within 30 days from diagnosis) with intensive therapy according to age and performance status.
Early death rates (within 30 days from diagnosis) with intensive therapy according to age and performance status. The numbers of patients are given in Table 1.
Gunnar Juliusson et al. Blood 2009;113:
©2009 by American Society of Hematology

5. Complete remission rates with intensive treatment according to age and WHO/ECOG performance status.
Complete remission rates with intensive treatment according to age and WHO/ECOG performance status. The numbers of patients are given in Table 1.
Gunnar Juliusson et al. Blood 2009;113:
©2009 by American Society of Hematology

6. Overall survival according to age irrespective of management (top, n = 2767), and patients with de novo AML, fit for intensive treatment, and with WHO/ECOG performance status 0 to II (bottom, n = 1229).
Overall survival according to age irrespective of management (top, n = 2767), and patients with de novo AML, fit for intensive treatment, and with WHO/ECOG performance status 0 to II (bottom, n = 1229).
Gunnar Juliusson et al. Blood 2009;113:
©2009 by American Society of Hematology

7. Overall survival according to WHO/ECOG performance status, only patients fit for intensive treatment.
Overall survival according to WHO/ECOG performance status, only patients fit for intensive treatment. Patients younger than 65 years (top, n = 864) and 65 to 79 years (bottom, n = 711).
Gunnar Juliusson et al. Blood 2009;113:
©2009 by American Society of Hematology

8. Overall survival of all patients, treated and untreated, 70 to 79 years of age according to geographic region, with different proportions of patients given intensive therapy (Table 4).
Overall survival of all patients, treated and untreated, 70 to 79 years of age according to geographic region, with different proportions of patients given intensive therapy (Table 4).
Gunnar Juliusson et al. Blood 2009;113:
©2009 by American Society of Hematology